| Autor: |
Petrova, L., Boiko, A., Batysheva, T., Gusev, E. |
| Předmět: |
|
| Zdroj: |
Neuroscience & Behavioral Physiology; May2012, Vol. 42 Issue 4, p327-337, 11p |
| Abstrakt: |
Published data show that 20-25 % of patients with multiple sclerosis (MS) have autoimmune thyroiditis and subclinical hypothyroidism before initiation of immunomodulatory treatment. No relationship has been found between thyroid gland pathology and demographic characteristics (age, gender), type of MS, rate of disease progression, or level of disability on the EDSS. Thyroid pathology in MS patients can be provoked or exacerbated by agents modifying the course of MS, i.e., disease-modifying treatments (DMT). Risk factors for the development of thyroid dysfunction on the background of β interferon (β-IFN) treatment are female gender and a history of autoimmune thyroid pathology. Clinical thyrotoxicosis is more dangerous, such that cessation of β-INF courses is required. We present here our own data on the state of the thyroid in 191 MS patients. Thyroid pathology was found in 34.6 % of MS patients in the form of nodules and subclinical hypothyroidism. Changes in thyroid function were seen in patients given Betaferon (β-IFN-1b); development of nodular goiter was seen in patients given glatiramer acetate (Copaxone). Thyroid structure and function were studied dynamically for one year on the background of DMT treatment. β-IFN-1b was found to provoke hypothyroidism. The need for thyroid tests in MS patients, especially during use of DMT, is identified. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink